関: focal myositis、idiopathic inflammatory myopathy、inflammatory muscle disease、myositis、proliferative myositis

WordNet

inflammation of muscle tissue
characterized or caused by inflammation; "an inflammatory process"; "an inflammatory response"
any pathology of the muscles that is not attributable to nerve dysfunction

PrepTutorEJDIC

炎症を起こす,炎症性の / 憤激させる,扇動的な

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/09/13 08:51:41」(JST)

wiki en

Inflammatory myopathy (inflammatory muscle disease or myositis) is disease featuring weakness and inflammation of muscles and (in some types) muscle pain. The cause of much inflammatory myopathy is unknown (idiopathic), and such cases are classified according to their symptoms and signs and electromyography, MRI and laboratory findings. The main classes of idiopathic inflammatory myopathy are polymyositis (PM), dermatomyositis (DM), and inclusion-body myositis (IBM).

Classification and diagnosis

There are a number of known causes of myopathy, and it is only once these have been ruled out that a clinician will assign an idiopathic inflammatory myopathy (IIM) syndrome to a case. The usual criteria for a diagnosis of PM are weakness in muscles of the head, neck, trunk, upper arms or upper legs; raised blood serum concentrations of some muscle enzymes such as creatine kinase; unhealthy muscle changes on electromyography; and biopsy findings of (i) muscle cell degeneration and regeneration and (ii) chronic inflammatory infiltrates in muscle cells. If heliotrope (purple) rash or Gottron's papules are also present, then the diagnosis is DM. In DM, myositis may not be clinically apparent but detectable via biopsy or MRI.^[1] If the criteria for PM are met but muscle weakness also affects the hands and feet or is not accompanied by pain IBM should be suspected, and confirmed when muscle cell biopsy reveals (i) cytoplasmic vacuoles fringed by basophilic granules and (ii) inflammatory infiltrate comprising mostly CD8 T lymphocytes and macrophages; and electron microscopy reveals filamentous inclusions in both cytoplasm and nucleus.^[2]

Treatment and management

There have been few randomized treatment trials, due to the relative rarity of inflammatory myopathies.^[3] The goal of treatment is improvement in activities of daily living and muscle strength. Suppression of immune system activity (immunosuppression) is the treatment strategy. Patients with PM or DM almost always improve to some degree in response to treatment, at least initially, and many recover fully with maintenance therapy. (If there is no initial improvement from treatment of PM or DM, the diagnosis should be carefully re-examined.) There is no proven effective therapy for IBM, and most IBM patients will need assistive devices such as a cane, a walking frame or a wheelchair. The later in life IBM arises, the more aggressive it appears to be.^[4]

Polymyositis and dermatomyositis

In severe cases of PM and DM with systemic signs, an initial three to five days on intravenous corticosteroid (methylprednisolone) may be used; but normally treatment begins with a single daily (after breakfast) high dose of oral corticosteroid (prednisone). After a month or so the strength of every second day's dose is very gradually reduced over three to four months, to minimize the negative effects of the prednisone. When a high dose of prednisone cannot be reduced without losing muscle strength, or when prednisone is effective but it is producing significant complications, "steroid sparing" oral immunosuppressants such as azathioprine, mycophenolate mofetil, methotrexate and cyclosporine, may be used in combination with reduced prednisone. Some of these steroid sparing drugs can take several months to demonstrate an effect.^[4]

To minimize side effects, patients on corticosteroids should follow a strict high-protein, low-carbohydrate, low-salt diet; and with long-term corticosteroid use a daily calcium supplement and weekly vitamin D supplement (and a weekly dose of Fosamax for postmenopausal women) should be considered.^[4]

For patients not responding to this approach there is weak evidence supporting the use of intravenous immunoglobulin, ciclosporin, tacrolimus, mycophenolate mofetil and other agents; and trials of rituximab have indicated a potential therapeutic effect.^[3]

Inclusion-body myositis

Despite its very similar clinical presentation to PM, IBM does not respond to the drugs that effectively treat PM, and there is no proven effective therapy for IBM.^[4] Alemtuzumab is being studied but as of May 2013 it had not demonstrated clinical effectiveness in IBM.^[3] Dysphagia (difficulty swallowing) may be improved by intravenous immunoglobulin, though more trials are needed.^[5] Non-fatiguing, systematic strength-building exercise has demonstrated benefit.^[6] Occupational and rehabilitation therapists can offer good advice on walking without falling and performing fine motor tasks, and can provide appropriate canes, braces and wheelchairs. Speech pathologists can provide advice on preventing choking episodes and reducing the anxiety of an immanent aspiration for both patients and carers.^[4]

Epidemiology

Every year between 2.18 and 7.7 people per million receive a diagnosis of PM or DM.^[7] Around 3.2 children per million per year are diagnosed with DM (termed juvenile dermatomyositis), with an average age of onset of seven years. Diagnosis of adult DM commonly occurs between 30 and 50 years of age. PM is an adult disease, usually emerging after the age of twenty. PM and DM are more common in females, more common in Caucasians, and least common in Asians. At any given time, about 35.5 people per million have IBM; it emerges after the age of 30 (usually after 50), and may be more common in males.^[3]

References

^ Miller, Frederick W (10 June 2009). "Classification of Idiopathic Inflammatory Myopathies". In Kagen, Lawrence J. The Inflammatory Myopathies. Springer. pp. 23–36. ISBN 9781627038393.
^ Kagen, Lawrence J (10 June 2009). "Inclusion Body Myositis". The Inflammatory Myopathies. Springer. pp. 95–102. ISBN 9781627038393.
^ ^a ^b ^c ^d Holton, Janice L; Wedderburn, Lucy R; Hanna, Michael G (29 May 2013). "Polymyositis, Dermatomyositis and Inclusion Body Myositis". In Goebel, Hans H; Sewry, Caroline A; Weller, Roy O. Muscle Disease: Pathology and Genetics. John Wiley & Sons. pp. 747–781. ISBN 1-118-63549-3.
^ ^a ^b ^c ^d ^e Dalakas, Marinos C (8 September 2010). "Treatment and Management of Autoimmune Myopathies". In Bertorini, Tulio E. Neuromuscular Disorders. Elsevier Health Sciences. pp. 395–408. ISBN 9781437703726.
^ Cited in Dalakas, Marinos C (08 September 2010). "Treatment and Management of Autoimmune Myopathies". In Bertorini, Tulio E. Neuromuscular Disorders. Elsevier Health Sciences. pp. 395—408. ISBN 9781437703726:
- Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K (March 1997). "Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study". Neurology 48 (3): 712–6. doi:10.1212/wnl.48.3.712. PMID 9065553.
- Walter MC, Lochmüller H, Toepfer M et al. (January 2000). "High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study". J. Neurol. 247 (1): 22–8. doi:10.1007/s004150050005. PMID 10701893.
- Cherin P, Pelletier S, Teixeira A et al. (January 2002). "Intravenous immunoglobulin for dysphagia of inclusion body myositis". Neurology 58 (2): 326. doi:10.1212/wnl.58.2.326. PMID 11805271.
^ Spector SA, Lemmer JT, Koffman BM et al. (October 1997). "Safety and efficacy of strength training in patients with sporadic inclusion body myositis". Muscle Nerve 20 (10): 1242–8. doi:10.1002/(sici)1097-4598(199710)20:10<1242::aid-mus6>3.3.co;2-x. PMID 9324080. Cited in:
- Dalakas, Marinos C (08 September 2010). "Treatment and Management of Autoimmune Myopathies". In Bertorini, Tulio E. Neuromuscular Disorders. Elsevier Health Sciences. pp. 395—408. ISBN 9781437703726
^ Mastaglia FL, Garlepp MJ, Phillips BA, Zilko PJ (April 2003). "Inflammatory myopathies: clinical, diagnostic and therapeutic aspects". Muscle Nerve 27 (4): 407–25. doi:10.1002/mus.10313. PMID 12661042. Cited in:
- Holton, Janice L; Wedderburn, Lucy R; Hanna, Michael G (29 May 2013). "Polymyositis, Dermatomyositis and Inclusion Body Myositis". In Goebel, Hans H; Sewry, Caroline A; Weller, Roy O. Muscle Disease: Pathology and Genetics. John Wiley & Sons. pp. 747–781. ISBN 1-118-63549-3.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 炎症性ミオパチーの病因 pathogenesis of inflammatory myopathies
2. ウイルス性筋炎 viral myositis
3. 成人における皮膚筋炎および多発性筋炎の診断および鑑別診断 diagnosis and differential diagnosis of dermatomyositis and polymyositis in adults
4. 成人における皮膚筋炎および多発性筋炎の臨床症状 clinical manifestations of dermatomyositis and polymyositis in adults
5. 成人における皮膚筋炎および多発性筋炎の初期治療 initial treatment of dermatomyositis and polymyositis in adults

English Journal

Classical and Atypical Fibrodysplasia Ossificans Progressiva in India.

Madhuri V1,2, Santhanam M2, Sugumar LK2, Rajagopal K2, Chilbule SK1.
Annals of human genetics.Ann Hum Genet.2015 Jul;79(4):245-52. doi: 10.1111/ahg.12112. Epub 2015 Jun 9.
Fibrodysplasia Ossificans Progressiva (FOP) is a rare debilitating disorder characterized by congenital deformity of the great toes from infancy and postnatal heterotopic ossification. Activating mutations in the activin A receptor type 1 (ACVR1) gene are responsible for the disease. The most common
PMID 26058333

In the idiopathic inflammatory myopathies (IIM), do reactive oxygen species (ROS) contribute to muscle weakness?

Lightfoot AP1, McArdle A1, Jackson MJ1, Cooper RG1.
Annals of the rheumatic diseases.Ann Rheum Dis.2015 Jul;74(7):1340-1346. doi: 10.1136/annrheumdis-2014-207172. Epub 2015 Apr 28.
The idiopathic inflammatory myopathies (IIMs) are a group of rare autoimmune disorders, collectively known as myositis. Affected patients present with proximal muscle weakness, which usually improves following treatment with immunosuppressants, but often incompletely so, thus many patients remain we
PMID 26063809

[Neurological symptoms due to Mycoplasma pneumoniae infection in nine children].

Roussel P1, Poulat AL2, Romaszko JP3, Labbé A1, Sarret C4.
Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie.Arch Pediatr.2015 Jul;22(7):699-707. doi: 10.1016/j.arcped.2015.04.013. Epub 2015 Jun 3.
Mycoplasma pneumoniae infection is common in children. Extrapulmonary symptoms usually reveal as neurological symptoms, mainly as encephalitis with significant morbidity and mortality. Various other neurological presentations have also been reported. We describe a cohort of nine children with neurol
PMID 26047743

Japanese Journal

Inclusion body myositis with granuloma formation in muscle tissue

Neuromuscular Disorders 25(9), 706-712, 2015-09-01
NAID 120005661916

A Study of the Exercise Effect and Exercise Load Determined Using Perceived Exertion in Patients with the Subacute Phase of Inflammatory Myopathy

Journal of the Japanese Physical Therapy Association 18(1), 28-28, 2015
NAID 130005113992

抗PL-7抗体陽性筋炎の1例―anti-synthetase syndromeの臨床像と筋病理像の検討―

臨床神経学 55(11), 810-815, 2015
NAID 130005110870

Related Pictures

★リンクテーブル★

リンク元	「炎症性筋疾患」「focal myositis」「proliferative myositis」「inflammatory muscle disease」「炎症性ミオパシー」
拡張検索	「idiopathic inflammatory myopathy」
関連記事	「inflammatory」

「炎症性筋疾患」

Inflammatory myopathy
	Gottron's papules on the hand of a patient with juvenile dermatomyositis.
Classification and external resources
Specialty	neurology
ICD-10	M33, G72.4
ICD-9-CM	359.6, 710.3-710.4
DiseasesDB	29473
MeSH	D009220